美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Alumis Inc.

28.00

+0.35001.27%

成交量：56.23萬

成交額：1,587.42萬

市值：34.16億

市盈率：-7.26

高：28.60

開：27.55

低：27.45

收：27.65

52周最高：30.60

52周最低：2.76

股本：1.22億

流通股本：7,748.63萬

量比：0.57

換手率：0.73%

股息：- -

股息率：- -

每股收益(TTM):-3.8545

每股收益(LYR):-10.3816

淨資產收益率：-66.88%

總資產收益率：-61.46%

市淨率：8.88

市盈率(LYR):-2.70

資料載入中...

總覽公司新聞資訊公告

Alumis Inc.盤中異動下午盤股價大漲5.05%報25.76美元

Form 4 | Alumis Inc.董事 Akkaraju Srinivas 增持588,235股

老虎公告助手

Alumis Inc.盤中異動大幅上漲5.36%報22.22美元

ALUMIS INC.董事 Foresite Capital Management VI LLC 增持411,764股

老虎公告助手

ALUMIS Inc.董事 James B. Tananbaum 增持411,764股

老虎公告助手

異動解讀 | Alumis Inc.盤中大漲11.21%，因皮膚病藥物臨床試驗成功及1.75億美元股票發行

BUZZ-生物製藥公司 Alumis 開始發行 1.75 億美元股票後漲幅擴大

BUZZ--美國股票走勢-Shake Shack、Arrowhead 製藥公司、洛歇馬丁公司

美股異動 | 銀屑病藥物三期試驗取得積極結果 Alumis(ALMS.US)開盤飆升超154%

Alumis報告銀屑病藥物三期臨床試驗取得積極結果

老虎资讯综合

異動解讀 | 銀屑病藥物三期試驗達主要終點，Alumis Inc.盤中暴漲167.51%

BUZZ--美國股票走勢-Alkermes、Ball Corp、NovaBridge

Alumis高管稱Envudeucitinib與武田Zasocitinib相比"極具競爭力"

異動解讀 | Alumis Inc.盤前暴漲94.46%，皮膚病藥物Envudeucitinib後期試驗達主要目標

BUZZ-皮膚病藥物在後期試驗中達到主要目標後，Alumis 公司業績大增

Alumis股價盤前飆升17.2%至9.74美元，公司皮膚病藥物達成兩項後期試驗主要目標

Alumis公司Envudeucitinib在III期臨床項目中展現領先皮膚清除效果，領跑新一代口服斑塊狀銀屑病療法

Alumis公司Envudeucitinib展現與二期項目一致的良好安全性和耐受性

Alumis 皮膚病藥物達到兩項後期試驗的主要目標

Alumis公司Envudeucitinib治療系統性紅斑狼瘡的Lumus 2B期試驗頂線數據預計2026年第三季度公布

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/ALMS/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"ALMS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALMS\",,,,,undefined,":{"symbol":"ALMS","market":"US","secType":"STK","nameCN":"Alumis Inc.","latestPrice":28,"timestamp":1771958841489,"preClose":27.65,"halted":0,"volume":562312,"delay":0,"changeRate":0.012658227848101318,"floatShares":77486300,"shares":122000000,"eps":-3.8545,"marketStatus":"交易中","change":0.35,"latestTime":"02-24 13:47:34 EST","open":27.55,"high":28.6,"low":27.45,"amount":15874195.967136,"amplitude":0.041591,"askPrice":28,"askSize":446,"bidPrice":27.98,"bidSize":92,"shortable":3,"etf":0,"ttmEps":-3.8545,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1771966800000},"marketStatusCode":2,"adr":0,"listingDate":1719547200000,"exchange":"NASDAQ","adjPreClose":27.65,"preHourTrading":{"tag":"盘前","latestPrice":27.27,"preClose":27.65,"latestTime":"09:28 EST","volume":4956,"amount":135353.727348,"timestamp":1771943280001,"change":-0.38,"changeRate":-0.013743,"amplitude":0.03255},"postHourTrading":{"tag":"盘后","latestPrice":27.65,"preClose":27.65,"latestTime":"19:36 EST","volume":104387,"amount":2886316.305,"timestamp":1771893389506,"change":0,"changeRate":0,"amplitude":0.009042},"volumeRatio":0.565488,"impliedVol":1.0294,"impliedVolPercentile":0.3182},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALMS\",,,,,undefined,":{"symbol":"ALMS","floatShares":77486300,"roa":"-61.46%","roe":"-66.88%","lyrEps":-10.381567,"volumeRatio":0.565488,"shares":122000000,"dividePrice":0,"high":28.6,"amplitude":0.041591,"preClose":27.65,"low":27.45,"week52Low":2.7601,"pbRate":"8.88","psRate":"154.42","week52High":30.6,"institutionHeld":0,"latestPrice":28,"committee":-0.657993,"eps":-3.8545,"divideRate":0,"volume":562312,"delay":0,"ttmEps":-3.8545,"open":27.55,"prevYearClose":9.76,"prevWeekClose":27.97,"prevMonthClose":24.51,"prevQuarterClose":9.76,"fiveDayClose":26.58,"twentyDayClose":26.31,"sixtyDayClose":7.33},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ALMS\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-13","symbol":"ALMS","fiscalQuarterEnding":"2025/09","expectedEps":-0.92,"name":null,"time":"盤後","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"post","actualEps":-1.06},{"market":"US","date":"2025-08-13","symbol":"ALMS","fiscalQuarterEnding":"2025/06","expectedEps":-1.11,"name":null,"time":"盤後","type":"earning","dateTimestamp":1755057600000,"reportTimeType":"post","actualEps":-1.17},{"market":"US","date":"2025-05-14","symbol":"ALMS","fiscalQuarterEnding":"2025/03","expectedEps":-1.47,"name":null,"time":"盤後","type":"earning","dateTimestamp":1747195200000,"reportTimeType":"post","actualEps":-1.82},{"market":"US","date":"2025-03-19","symbol":"ALMS","fiscalQuarterEnding":"2024/12","expectedEps":-1.39,"name":null,"time":"盤後","type":"earning","dateTimestamp":1742356800000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-11-13","symbol":"ALMS","fiscalQuarterEnding":"2024/09","expectedEps":-1.64,"name":null,"time":"盤後","type":"earning","dateTimestamp":1731474000000,"reportTimeType":"post","actualEps":-1.73}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ALMS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ALMS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":8,"updateTime":1753592400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ALMS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ALMS","date":"2026-02-23","current":-7.173434,"percent":0.00241,"low":-14.850306,"twenty":-3.703939,"median":-2.076548,"eighty":-0.97079,"high":-0.443678,"avg":-2.975104,"sd":3.049644,"marketCap":3486646192},"quantilePoints":[{"date":"2024-06-28","current":-4.084559,"twenty":-4.913756,"median":-4.913756,"eighty":-4.416238,"marketCap":689534895},{"date":"2024-07-05","current":-3.516406,"twenty":-4.747917,"median":-3.851156,"eighty":-3.59564,"marketCap":593622147},{"date":"2024-07-12","current":-3.405847,"twenty":-4.063676,"median":-3.825051,"eighty":-3.58397,"marketCap":574958044},{"date":"2024-07-19","current":-4.023985,"twenty":-4.026561,"median":-3.851156,"eighty":-3.52869,"marketCap":679309112},{"date":"2024-07-26","current":-4.023985,"twenty":-4.117224,"median":-3.947896,"eighty":-3.58397,"marketCap":679309112},{"date":"2024-08-02","current":-4.178507,"twenty":-4.123137,"median":-3.980142,"eighty":-3.620209,"marketCap":705394582},{"date":"2024-08-09","current":-3.850149,"twenty":-4.108328,"median":-3.938677,"eighty":-3.693301,"marketCap":649962958},{"date":"2024-08-16","current":-3.683794,"twenty":-4.085032,"median":-3.914533,"eighty":-3.659692,"marketCap":696362265},{"date":"2024-08-23","current":-3.672282,"twenty":-4.078883,"median":-3.855481,"eighty":-3.667968,"marketCap":694186133},{"date":"2024-08-30","current":-3.655014,"twenty":-4.050383,"median":-3.84693,"eighty":-3.659692,"marketCap":690921935},{"date":"2024-09-06","current":-3.442045,"twenty":-4.027205,"median":-3.798947,"eighty":-3.608967,"marketCap":650663491},{"date":"2024-09-13","current":-3.33556,"twenty":-4.023985,"median":-3.741353,"eighty":-3.511116,"marketCap":630534270},{"date":"2024-09-20","current":-3.301025,"twenty":-4.023985,"median":-3.709695,"eighty":-3.405847,"marketCap":624005873},{"date":"2024-09-27","current":-3.211808,"twenty":-3.980142,"median":-3.685233,"eighty":-3.395997,"marketCap":607140850},{"date":"2024-10-04","current":-2.803137,"twenty":-3.959602,"median":-3.672282,"eighty":-3.303903,"marketCap":529888161},{"date":"2024-10-11","current":-2.978693,"twenty":-3.946725,"median":-3.656453,"eighty":-3.263611,"marketCap":563074175},{"date":"2024-10-18","current":-3.462191,"twenty":-3.930629,"median":-3.608967,"eighty":-3.220442,"marketCap":654471723},{"date":"2024-10-25","current":-3.424777,"twenty":-3.915649,"median":-3.608753,"eighty":-3.22332,"marketCap":647399293},{"date":"2024-11-01","current":-3.254977,"twenty":-3.914533,"median":-3.516406,"eighty":-3.231953,"marketCap":615301345},{"date":"2024-11-08","current":-3.459313,"twenty":-3.86344,"median":-3.50536,"eighty":-3.240587,"marketCap":653927690},{"date":"2024-11-15","current":-2.016571,"twenty":-3.859807,"median":-3.465068,"eighty":-3.22332,"marketCap":481504843},{"date":"2024-11-22","current":-2.155567,"twenty":-3.851156,"median":-3.454996,"eighty":-3.18015,"marketCap":514693313},{"date":"2024-11-29","current":-2.109995,"twenty":-3.85035,"median":-3.444923,"eighty":-3.067334,"marketCap":503811848},{"date":"2024-12-06","current":-2.050751,"twenty":-3.847574,"median":-3.439167,"eighty":-2.978693,"marketCap":489665943},{"date":"2024-12-13","current":-1.911755,"twenty":-3.823752,"median":-3.419021,"eighty":-2.94646,"marketCap":456477473},{"date":"2024-12-20","current":-2.009736,"twenty":-3.802749,"median":-3.405847,"eighty":-2.329653,"marketCap":479872624},{"date":"2024-12-27","current":-1.836561,"twenty":-3.764391,"median":-3.395997,"eighty":-2.153744,"marketCap":438523055},{"date":"2025-01-03","current":-1.925427,"twenty":-3.741353,"median":-3.367218,"eighty":-2.142807,"marketCap":459741913},{"date":"2025-01-10","current":-1.595028,"twenty":-3.741353,"median":-3.312536,"eighty":-2.023407,"marketCap":380851289},{"date":"2025-01-17","current":-1.745417,"twenty":-3.740777,"median":-3.298147,"eighty":-1.989684,"marketCap":416760124},{"date":"2025-01-24","current":-1.522113,"twenty":-3.738475,"median":-3.27944,"eighty":-1.964163,"marketCap":363440944},{"date":"2025-01-31","current":-1.704402,"twenty":-3.735597,"median":-3.263611,"eighty":-1.93682,"marketCap":406966805},{"date":"2025-02-07","current":-1.291973,"twenty":-3.709695,"median":-3.247782,"eighty":-1.911755,"marketCap":308489544},{"date":"2025-02-14","current":-1.187157,"twenty":-3.703939,"median":-3.22332,"eighty":-1.873019,"marketCap":283462173},{"date":"2025-02-21","current":-1.178042,"twenty":-3.690125,"median":-3.211808,"eighty":-1.829725,"marketCap":281285880},{"date":"2025-02-28","current":-1.059555,"twenty":-3.68437,"median":-3.162882,"eighty":-1.759544,"marketCap":252994070},{"date":"2025-03-07","current":-1.111963,"twenty":-3.676887,"median":-3.070787,"eighty":-1.711693,"marketCap":265507755},{"date":"2025-03-14","current":-1.041326,"twenty":-3.672858,"median":-3.006033,"eighty":-1.678881,"marketCap":248641484},{"date":"2025-03-21","current":-0.693421,"twenty":-3.667968,"median":-2.978693,"eighty":-1.565406,"marketCap":204027476},{"date":"2025-03-28","current":-1.042906,"twenty":-3.659692,"median":-2.965742,"eighty":-1.505251,"marketCap":306857324},{"date":"2025-04-04","current":-1.85837,"twenty":-3.65559,"median":-2.803137,"eighty":-1.500694,"marketCap":546793636},{"date":"2025-04-11","current":-1.198232,"twenty":-3.63199,"median":-2.286587,"eighty":-1.463027,"marketCap":352559478},{"date":"2025-04-17","current":-0.924562,"twenty":-3.622781,"median":-2.176074,"eighty":-1.280365,"marketCap":272036635},{"date":"2025-04-25","current":-0.791425,"twenty":-3.613572,"median":-2.146452,"eighty":-1.183511,"marketCap":232863359},{"date":"2025-05-02","current":-0.848748,"twenty":-3.60871,"median":-2.125945,"eighty":-1.162092,"marketCap":249729630},{"date":"2025-05-09","current":-0.930109,"twenty":-3.590112,"median":-2.016571,"eighty":-1.140673,"marketCap":273668854},{"date":"2025-05-16","current":-0.890525,"twenty":-3.561975,"median":-1.997203,"eighty":-1.105127,"marketCap":305759157},{"date":"2025-05-23","current":-0.766929,"twenty":-3.530406,"median":-1.968721,"eighty":-1.070948,"marketCap":263322832},{"date":"2025-05-30","current":-0.619565,"twenty":-3.51429,"median":-1.964163,"eighty":-1.045883,"marketCap":212725677},{"date":"2025-06-06","current":-0.530829,"twenty":-3.506511,"median":-1.95277,"eighty":-1.037224,"marketCap":182258572},{"date":"2025-06-13","current":-0.503891,"twenty":-3.48667,"median":-1.925427,"eighty":-0.984896,"marketCap":173009629},{"date":"2025-06-20","current":-0.476954,"twenty":-3.466829,"median":-1.916313,"eighty":-0.943233,"marketCap":163760687},{"date":"2025-06-27","current":-0.522906,"twenty":-3.464493,"median":-1.909477,"eighty":-0.920124,"marketCap":179538295},{"date":"2025-07-03","current":-0.538752,"twenty":-3.462191,"median":-1.878715,"eighty":-0.88573,"marketCap":184978849},{"date":"2025-07-11","current":-0.564105,"twenty":-3.459313,"median":-1.85837,"eighty":-0.848748,"marketCap":193683736},{"date":"2025-07-18","current":-0.556182,"twenty":-3.450679,"median":-1.833144,"eighty":-0.808067,"marketCap":190963459},{"date":"2025-07-25","current":-0.611642,"twenty":-3.444923,"median":-1.819538,"eighty":-0.791425,"marketCap":210005399},{"date":"2025-08-01","current":-0.65601,"twenty":-3.444923,"median":-1.768203,"eighty":-0.766929,"marketCap":225238952},{"date":"2025-08-08","current":-1.301335,"twenty":-3.442045,"median":-1.745417,"eighty":-0.761839,"marketCap":446809517},{"date":"2025-08-15","current":-2.007939,"twenty":-3.439167,"median":-1.743138,"eighty":-0.765537,"marketCap":456842285},{"date":"2025-08-22","current":-2.103991,"twenty":-3.427655,"median":-1.761367,"eighty":-0.766929,"marketCap":478695789},{"date":"2025-08-29","current":-2.14973,"twenty":-3.424777,"median":-1.805264,"eighty":-0.766929,"marketCap":489102219},{"date":"2025-09-05","current":-2.103991,"twenty":-3.415567,"median":-1.826307,"eighty":-0.771366,"marketCap":478695789},{"date":"2025-09-12","current":-1.994217,"twenty":-3.40866,"median":-1.836561,"eighty":-0.773109,"marketCap":453720356},{"date":"2025-09-19","current":-1.9622,"twenty":-3.406179,"median":-1.867544,"eighty":-0.787793,"marketCap":446435855},{"date":"2025-09-26","current":-1.824983,"twenty":-3.405847,"median":-1.875296,"eighty":-0.795863,"marketCap":415216564},{"date":"2025-10-03","current":-1.811262,"twenty":-3.397967,"median":-1.860219,"eighty":-0.799931,"marketCap":412094635},{"date":"2025-10-10","current":-2.071974,"twenty":-3.391392,"median":-1.873019,"eighty":-0.803629,"marketCap":471411288},{"date":"2025-10-17","current":-2.108565,"twenty":-3.371823,"median":-1.884428,"eighty":-0.807327,"marketCap":479736432},{"date":"2025-10-24","current":-2.108565,"twenty":-3.341892,"median":-1.893592,"eighty":-0.812505,"marketCap":479736432},{"date":"2025-10-31","current":-2.131434,"twenty":-3.317141,"median":-1.904969,"eighty":-0.82249,"marketCap":484939647},{"date":"2025-11-07","current":-2.158878,"twenty":-3.30563,"median":-1.911755,"eighty":-0.843135,"marketCap":491183505},{"date":"2025-11-14","current":-2.422653,"twenty":-3.301601,"median":-1.918592,"eighty":-0.848547,"marketCap":551197167},{"date":"2025-11-21","current":-2.946741,"twenty":-3.29642,"median":-1.93682,"eighty":-0.86502,"marketCap":722402348},{"date":"2025-11-28","current":-3.266113,"twenty":-3.290089,"median":-1.953052,"eighty":-0.869088,"marketCap":800697401},{"date":"2025-12-05","current":-3.534386,"twenty":-3.297571,"median":-1.962042,"eighty":-0.870197,"marketCap":866465244},{"date":"2025-12-12","current":-4.943882,"twenty":-3.336738,"median":-1.966442,"eighty":-0.879813,"marketCap":1212007408},{"date":"2025-12-19","current":-4.709675,"twenty":-3.399937,"median":-1.972322,"eighty":-0.888607,"marketCap":1154591037},{"date":"2025-12-26","current":-4.854457,"twenty":-3.410963,"median":-1.990368,"eighty":-0.898223,"marketCap":1190084794},{"date":"2026-01-02","current":-4.156097,"twenty":-3.436865,"median":-1.996504,"eighty":-0.911618,"marketCap":1018879613},{"date":"2026-01-09","current":-7.741582,"twenty":-3.449528,"median":-2.003365,"eighty":-0.920124,"marketCap":1897872066},{"date":"2026-01-16","current":-12.290084,"twenty":-3.466829,"median":-2.013154,"eighty":-0.925671,"marketCap":3012950964},{"date":"2026-01-23","current":-13.362987,"twenty":-3.516406,"median":-2.019374,"eighty":-0.930109,"marketCap":3275976472},{"date":"2026-01-30","current":-13.647739,"twenty":-3.577828,"median":-2.030809,"eighty":-0.937506,"marketCap":3345784190},{"date":"2026-02-06","current":-13.393497,"twenty":-3.626234,"median":-2.053678,"eighty":-0.942816,"marketCap":3283455871},{"date":"2026-02-13","current":-13.6274,"twenty":-3.672282,"median":-2.062826,"eighty":-0.944902,"marketCap":3340797925},{"date":"2026-02-20","current":-14.850306,"twenty":-3.690125,"median":-2.071974,"eighty":-0.965612,"marketCap":3640597141},{"date":"2026-02-23","current":-14.222327,"twenty":-3.703939,"median":-2.076548,"eighty":-0.97079,"marketCap":3486646192}],"updateTime":1771940220244},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ALMS\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2606782703","title":"Alumis Inc.盤中異動 下午盤股價大漲5.05%報25.76美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2606782703","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606782703?lang=zh_tw&edition=fundamental","pubTime":"2026-01-27 03:03","pubTimestamp":1769454236,"startTime":"0","endTime":"0","summary":"北京时间2026年01月27日03时03分，Alumis Inc.股票出现波动，股价快速拉升5.05%。截至发稿，该股报25.76美元/股，成交量122.962万股，换手率0.99%，振幅9.30%。Alumis Inc.股票所在的生物技术行业中，整体涨幅为0.75%。Alumis Inc.公司简介：Alumis Inc 是一家处于临床阶段的生物制药公司，专注于识别、收购并加速开发和商业化用于自身免疫性疾病的变革性药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260127030356a6af5b7e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260127030356a6af5b7e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","ALMS"],"gpt_icon":0},{"id":"1172404239","title":"Form 4 | Alumis Inc.董事 Akkaraju Srinivas 增持588,235股","url":"https://stock-news.laohu8.com/highlight/detail?id=1172404239","media":"老虎公告助手","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172404239?lang=zh_tw&edition=fundamental","pubTime":"2026-01-14 07:25","pubTimestamp":1768346733,"startTime":"0","endTime":"0","summary":"Alumis Inc.的董事 Akkaraju Srinivas 于2026年1月9日通过 Samsara Opportunity Fund, L.P.增持了588,235股普通股，定价为每股$17。交易显示其对公司未来发展的信心，中长期来看可能带来积极影响。个人持股通过间接形式持有，目前总计持有1,853,488股，这一点值得投资者注意。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Form 4 | Alumis Inc.董事 Akkaraju Srinivas 增持588,235股","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS"],"gpt_icon":0},{"id":"2603634859","title":"Alumis Inc.盤中異動 大幅上漲5.36%報22.22美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2603634859","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603634859?lang=zh_tw&edition=fundamental","pubTime":"2026-01-14 00:11","pubTimestamp":1768320716,"startTime":"0","endTime":"0","summary":"北京时间2026年01月14日00时11分，Alumis Inc.股票出现异动，股价急速上涨5.36%。截至发稿，该股报22.22美元/股，成交量143.667万股，换手率1.15%，振幅8.97%。Alumis Inc.股票所在的生物技术行业中，整体跌幅为0.14%。Alumis Inc.公司简介：Alumis Inc 是一家处于临床阶段的生物制药公司，专注于识别、收购并加速开发和商业化用于自身免疫性疾病的变革性药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260114001156a4bf91be&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260114001156a4bf91be&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","ALMS"],"gpt_icon":1},{"id":"1180282206","title":"ALUMIS INC.董事 Foresite Capital Management VI LLC 增持411,764股","url":"https://stock-news.laohu8.com/highlight/detail?id=1180282206","media":"老虎公告助手","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180282206?lang=zh_tw&edition=fundamental","pubTime":"2026-01-13 11:20","pubTimestamp":1768274427,"startTime":"0","endTime":"0","summary":"ALUMIS INC. 董事 Foresite Capital Management VI LLC 于2026年1月8日进行了2次增持，总计购买411,764股，每股价格为17美元。增持后其持股量增加，通常被视为利好信号，可能预示着公司未来发展前景良好，值得投资者关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS"],"gpt_icon":0},{"id":"1181767663","title":"ALUMIS Inc.董事 James B. Tananbaum 增持411,764股","url":"https://stock-news.laohu8.com/highlight/detail?id=1181767663","media":"老虎公告助手","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181767663?lang=zh_tw&edition=fundamental","pubTime":"2026-01-13 11:12","pubTimestamp":1768273933,"startTime":"0","endTime":"0","summary":"ALUMIS Inc. (ALMS) 董事 James B. Tananbaum 于2026年1月8日进行增持，购买了411,764股普通股票。此次增持每股价格为17美元。在购买后，James B. Tananbaum通过间接形式分别持有5,702,536股、2,908,332股、4,247,670股、194,459股、1,960,337股以及1,176,470股普通股票。董事的增持通常传递出对公司未来前景的信心，是一个利好信号，投资者可以关注公司后续表现。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"ALUMIS Inc.董事 James B. Tananbaum 增持411,764股","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS"],"gpt_icon":0},{"id":"1107964214","title":"異動解讀 | Alumis Inc.盤中大漲11.21%，因皮膚病藥物臨床試驗成功及1.75億美元股票發行","url":"https://stock-news.laohu8.com/highlight/detail?id=1107964214","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107964214?lang=zh_tw&edition=fundamental","pubTime":"2026-01-07 23:38","pubTimestamp":1767800321,"startTime":"0","endTime":"0","summary":"生物制药公司Alumis Inc.（ALMS）今日盘中大涨11.21%，股价表现强劲。消息面上，该公司的皮肤病药物envudeucitinib在两项后期研究中达到了主要目标，这增强了市场对其药物获批的信心。此外，公司宣布开始1.75亿美元的股票发行，计划将募集资金用于向美国FDA提交潜在的上市申请、envudeucitinib的上市准备工作以及其他临床开发项目。分析师普遍看好该股，所有8位分析师均给予正面评级，其中4位为“强烈买入”。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ALMS"],"gpt_icon":0},{"id":"2601855804","title":"BUZZ-生物製藥公司 Alumis 開始發行 1.75 億美元股票後漲幅擴大","url":"https://stock-news.laohu8.com/highlight/detail?id=2601855804","media":"路透中文","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601855804?lang=zh_tw&edition=fundamental","pubTime":"2026-01-07 22:53","pubTimestamp":1767797630,"startTime":"0","endTime":"0","summary":"** Alumis ALMS.O股价周三早盘上涨9.1%，报17.71美元，该生物制药公司在上一交易日股价飙升至历史新高后寻求注资。** 该公司的皮肤病药物envudeucitinib在两项后期研究中达到了主要目标 ，ALMS股价周二上涨了一倍多，收于16.23美元，涨幅达95%。** 周二收盘后，这家位于旧金山南部的公司开始  1.75 亿美元的股票发行。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nL4T3Y812V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0795875169.SGD","IE00BJJMRZ35.SGD","LU0971096721.USD","LU1791710582.SGD","LU1868836591.USD","LU1868836757.USD","BK4559","BK4534","BK4007","LU0306807586.USD","IE00BSNM7G36.USD","IE00BJT1NW94.SGD","LU1989772923.USD","LU2347655156.SGD","LU0106831901.USD","LU2360032135.SGD","LU1989771016.USD","LU1791710400.SGD","LU1244550494.USD","LU1670711040.USD","LU2133065610.SGD","LU0114720955.EUR","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","LU1244550221.USD","LU2242652126.USD","BK4504","ALMS","LU1670711123.USD","LU0237698245.USD","BK4581","LU0158827948.USD","LU0234570918.USD","LU1548497426.USD","LU1989772840.SGD","LU1363072403.SGD","LU2242646821.SGD","BMY","LU0106261372.USD","LU1668664300.SGD","LU0061475181.USD","LU0267386448.USD","BK4588","LU2028103732.USD","LU2125154778.USD","LU1430594728.SGD","LU1093756168.USD","LU1323610961.USD","LU0456855351.SGD","LU0006306889.USD"],"gpt_icon":1},{"id":"2601819819","title":"BUZZ--美國股票走勢-Shake Shack、Arrowhead 製藥公司、洛歇馬丁公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2601819819","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601819819?lang=zh_tw&edition=fundamental","pubTime":"2026-01-06 23:52","pubTimestamp":1767714728,"startTime":"0","endTime":"0","summary":".N美国东部时间10:30，道琼斯工业平均指数.DJI上涨0.42%，报49,184.92点。标普 500 指数.SPX上涨 0.42%，报 6,931.22 点；纳斯达克综合指数.IXIC上涨 0.49%，报 23,508.79 点。。nL4N3Y70PF ** CoreWeave Inc CRWV.O:BUZZ - 因 Truist 开始报道而获得 \"持有 \"评级；股价","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nL4S3Y710Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SHAK","STAA","BK","VST","STT","CDE","NBP","O","DLR","GL","REGN","UAA","APGE","FERG","ALKS","HL","CORZ","PNC","INTU","LMT","ACN","TFC","AIG","ALB","CFG","VRTX","ZETA","CRNX","JXN","IMSR","GILD","EPAM","MCHP","NTRS","AEVA","ANGO","BALL","ACRS","OS","BAC","ALMS","IFF","GNPX","EQIX","NEM"],"gpt_icon":1},{"id":"2601815301","title":"美股異動 | 銀屑病藥物三期試驗取得積極結果 Alumis(ALMS.US)開盤飆升超154%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601815301","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601815301?lang=zh_tw&edition=fundamental","pubTime":"2026-01-06 22:40","pubTimestamp":1767710453,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周二，Alumis开盘飙升超154%，创历史新高，报20.60美元。消息面上，该公司宣布了其envudeucitinib三期ONWARD1和ONWARD2临床试验的积极顶线结果。在这些试验中，Envudeucitinib在第16周的银屑病面积和严重程度指数75和静态医生整体评估0/1共同主要终点上，相对于安慰剂表现出更优的皮肤清除效果。在ONWARD1和ONWARD2中平均来看，74%的患者达到PASI 75，59%的患者达到sPGA 0/1，随着时间推移反应加深。此外，两个试验之间共同主要终点的安慰剂校正响应率保持一致。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1389551.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ALMS","BK4007"],"gpt_icon":1},{"id":"1174899077","title":"Alumis報告銀屑病藥物三期臨床試驗取得積極結果","url":"https://stock-news.laohu8.com/highlight/detail?id=1174899077","media":"老虎资讯综合","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174899077?lang=zh_tw&edition=fundamental","pubTime":"2026-01-06 22:38","pubTimestamp":1767710300,"startTime":"0","endTime":"0","summary":"Alumis一度飙升近120%！报告银屑病药物三期临床试验取得积极结果。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"ff7d18fe305d0508493cad3a6b784395","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Alumis报告银屑病药物三期临床试验取得积极结果","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS"],"gpt_icon":0},{"id":"1152649084","title":"異動解讀 | 銀屑病藥物三期試驗達主要終點，Alumis Inc.盤中暴漲167.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=1152649084","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152649084?lang=zh_tw&edition=fundamental","pubTime":"2026-01-06 22:32","pubTimestamp":1767709963,"startTime":"0","endTime":"0","summary":"Alumis Inc.今日盘中股价飙升167.51%，创下历史性涨幅。这一剧烈波动源于公司宣布其口服TYK2抑制剂Envudeucitinib在治疗中重度斑块状银屑病的两项三期临床试验中均达到主要终点。试验数据显示，约65%的患者在24周治疗后实现皮肤症状改善90%以上，40%以上患者达到完全清除，疗效显著优于安慰剂及安进公司的口服药Otezla。公司计划2026年下半年提交FDA申请，若获批将与百时美施贵宝的Sotyktu展开竞争。此次突破性数据显著提升了市场对Alumis商业化前景的预期。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"ff7d18fe305d0508493cad3a6b784395","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ALMS"],"gpt_icon":0},{"id":"2601818061","title":"BUZZ--美國股票走勢-Alkermes、Ball Corp、NovaBridge","url":"https://stock-news.laohu8.com/highlight/detail?id=2601818061","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601818061?lang=zh_tw&edition=fundamental","pubTime":"2026-01-06 22:12","pubTimestamp":1767708747,"startTime":"0","endTime":"0","summary":".N** 国际香精香料公司IFF.N：BUZZ - MS看好配料领域的 \"结构性赢家\"，减持帝斯曼股票，增持吉娃丹股票。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nL4T3Y70VL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AEVA","NBP","NVDS","IFF","AIG","ALMS","STT","NVDS.UK","APGE","ALKS","OS","2NVD.UK","VERX","FERG","MCHP","BK","NVDU","GNPX","ANGO","CRNX","INTU","NTRS","ALB","O","RTO.UK","GILD","BALL","JXN","NVD","VRTX","UAA","CDE","REGN","NEM","NVDY","VST","ACRS","3NVD.UK","HL","AU","HGT.UK","NVDX","ZETA","ACN","GL"],"gpt_icon":1},{"id":"1154857920","title":"Alumis高管稱Envudeucitinib與武田Zasocitinib相比\"極具競爭力\"","url":"https://stock-news.laohu8.com/highlight/detail?id=1154857920","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154857920?lang=zh_tw&edition=fundamental","pubTime":"2026-01-06 21:34","pubTimestamp":1767706444,"startTime":"0","endTime":"0","summary":"在电话会议中，Alumis Inc.高管表示，公司坚信其研发的Envudeucitinib与武田制药的Zasocitinib相比具有显著竞争优势。该表态凸显了企业对自身产品疗效的信心，也预示着自身免疫疾病治疗领域可能迎来新的竞争格局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"ff7d18fe305d0508493cad3a6b784395","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS","BK4007"],"gpt_icon":0},{"id":"1138061905","title":"異動解讀 | Alumis Inc.盤前暴漲94.46%，皮膚病藥物Envudeucitinib後期試驗達主要目標","url":"https://stock-news.laohu8.com/highlight/detail?id=1138061905","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1138061905?lang=zh_tw&edition=fundamental","pubTime":"2026-01-06 21:02","pubTimestamp":1767704545,"startTime":"0","endTime":"0","summary":"Alumis Inc.今日盘前股价暴涨94.46%，创下显著涨幅，引发市场广泛关注。这一股价飙升的直接原因是公司宣布其研发的皮肤病药物Envudeucitinib在两项后期临床试验中成功达到主要研究终点。分析人士指出，Envudeucitinib通过阻断TYK2蛋白发挥作用，减少导致银屑病的过度免疫反应，其疗效接近最畅销的注射药物，具有成为同类领先TYK2抑制剂的潜力。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"ff7d18fe305d0508493cad3a6b784395","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ALMS"],"gpt_icon":0},{"id":"2601944428","title":"BUZZ-皮膚病藥物在後期試驗中達到主要目標後，Alumis 公司業績大增","url":"https://stock-news.laohu8.com/highlight/detail?id=2601944428","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601944428?lang=zh_tw&edition=fundamental","pubTime":"2026-01-06 20:15","pubTimestamp":1767701742,"startTime":"0","endTime":"0","summary":"** Alumis计划于2026年下半年向美国FDA提交上市申请** 在过去12个月中，股价累计下跌14.9 (为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"ff7d18fe305d0508493cad3a6b784395","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nL4S3Y70QO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS","BK4007"],"gpt_icon":0},{"id":"1165494801","title":"Alumis股價盤前飆升17.2%至9.74美元，公司皮膚病藥物達成兩項後期試驗主要目標","url":"https://stock-news.laohu8.com/highlight/detail?id=1165494801","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165494801?lang=zh_tw&edition=fundamental","pubTime":"2026-01-06 20:09","pubTimestamp":1767701353,"startTime":"0","endTime":"0","summary":"Alumis Inc. (ALMS) 股价在盘前交易中大幅上涨17.2%，报收于每股9.74美元。这一强劲表现源于公司宣布其研发的皮肤病药物在两项后期临床试验中，均已成功达到预设的主要研究终点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"ff7d18fe305d0508493cad3a6b784395","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS","BK4007"],"gpt_icon":0},{"id":"1185233710","title":"Alumis公司Envudeucitinib在III期臨床項目中展現領先皮膚清除效果，領跑新一代口服斑塊狀銀屑病療法","url":"https://stock-news.laohu8.com/highlight/detail?id=1185233710","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1185233710?lang=zh_tw&edition=fundamental","pubTime":"2026-01-06 20:08","pubTimestamp":1767701322,"startTime":"0","endTime":"0","summary":"Alumis公司旗下药物Envudeucitinib在其III期临床项目中展现出卓越疗效，其皮肤清除效果在新一代口服斑块状银屑病疗法中处于领先地位。该药物在临床试验中表现出显著优势，为斑块状银屑病患者提供了新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"ff7d18fe305d0508493cad3a6b784395","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS","BK4007"],"gpt_icon":0},{"id":"1158074253","title":"Alumis公司Envudeucitinib展現與二期項目一致的良好安全性和耐受性","url":"https://stock-news.laohu8.com/highlight/detail?id=1158074253","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158074253?lang=zh_tw&edition=fundamental","pubTime":"2026-01-06 20:05","pubTimestamp":1767701105,"startTime":"0","endTime":"0","summary":"Alumis公司宣布，其候选药物Envudeucitinib在临床研究中展现出良好的安全性和耐受性特征，这一结果与二期临床试验项目的数据保持一致。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"ff7d18fe305d0508493cad3a6b784395","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS","BK4007"],"gpt_icon":0},{"id":"2601945298","title":"Alumis 皮膚病藥物達到兩項後期試驗的主要目標","url":"https://stock-news.laohu8.com/highlight/detail?id=2601945298","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601945298?lang=zh_tw&edition=fundamental","pubTime":"2026-01-06 20:04","pubTimestamp":1767701087,"startTime":"0","endTime":"0","summary":"Alumis 皮肤病药物达到两项后期试验的主要目标路透1月6日 - Alumis ALMS.O周二称，其实验性药片在对一种皮肤病患者进行的两项后期研究中达到了主要目标。(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nL4S3Y70Q2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS","BK4007"],"gpt_icon":0},{"id":"1122336632","title":"Alumis公司Envudeucitinib治療系統性紅斑狼瘡的Lumus 2B期試驗頂線數據預計2026年第三季度公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1122336632","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122336632?lang=zh_tw&edition=fundamental","pubTime":"2026-01-06 20:03","pubTimestamp":1767700994,"startTime":"0","endTime":"0","summary":"Alumis公司宣布，其用于治疗系统性红斑狼疮的在研药物Envudeucitinib，其名为Lumus的2B期临床试验的顶线结果，预计将于2026年第三季度揭晓。这一关键数据节点备受市场关注，将直接影响该药物的后续开发路径。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS","BK4007"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":29,"code":"91000000","status":"200"}]}}